111In-pentetreotide scintigraphy in medulloblastoma: A comparison with magnetic resonance imaging

Acta Oncologica

Volumn 46, Issue 1, 2007, Pages 111-117

  Yüksel, Mahmut ^a,b,d   Lutterbey, Götz ^b   Biersack, Hans Jürgen ^b   Elke, Urs ^b   Hasan, Carola ^b   Gao, Zairong ^c   Bode, Udo ^b   Ezziddin, Samer ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b UNIVERSITY OF BONN   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN;

ADOLESCENT; ADULT; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; MEDULLOBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ARTICLE; CEREBELLUM TUMOR; COMPARATIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDULLOBLASTOMA; PREDICTIVE VALUE OF TESTS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 33847050908     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600833152     Document Type: Review

References (34)

1. Reddy AT, Packer RJ. Medulloblastoma. Curr Opin Neurol 1999;12:681-5.
2. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-8.
3. Dunkel IJ, Finlay JL. High dose chemotherapy with autologues stem cell rescue for patients with medulloblastoma. J Neurooncol 1996;29:69-74.
4. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
5. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9.
6. Reubi JC, Lang W, Maurer R. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-64.
7. Muller HL, Fruhwald MC, Scheubeck M, Rendl J, Warmuth-Metz M, Sorensen N, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol 1998;38:27-40.
8. 2) in medulloblastoma: Implications for diagnosis and therapy. Pediatr Res 1999;45:697-708.
9. Beutler D, Avoledo P, Reubi JC, Macke HR, Muller-Brand J, Merlo A, et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA(0)-D-Phe(1)-Tyr(3)-octreotide radiopeptide brachytherapy. Cancer 2005;103:869-73.
10. Meyers SP, Kemp SS, Tarr RW. MR imaging features of medullobastomas. Am J Roentgenol 1992;158:859-65.
11. Tomita T, Das L, Radkowski MA. Bone metastases of medulloblastoma in childhood; correlation with flow cytometric DNA analysis. J Neurooncol 1990;8:113-20.
12. Ersahin Y, Yararbas U, Duman Y, Mutluer S. Single photon emission tomography following posterior fossa surgery in patients with and without mutism. Childs Nerv Syst 2002;18:318-25.
13. Sagiuchi T, Ishii K, Asano Y, Aoki Y, Kikuchi K, Jinguuji K, et al. Bilateral crossed cerebello-cerebral diaschisis and mutism after surgery for cerebellar medulloblastoma. Ann Nucl Med 2001;15:157-60.
14. Chamberlain MC. Pediatric leptomeningeal metastasis: 111In-DTPA cerebrospinal fluid flow studies. J Child Neurol 1994;9:150-4.
15. Naitoh Y, Sasajima T, Kinouchi H, Mikawa S, Mizoi K. Medulloblastoma with extensive nodularity: Single photon emission CT study with iodine-123 metaiodobenzylguanidine. Am J Neuroradiol 2002;23:1564-7.
16. Rollins NK, Lowry PA, Shapiro KN. Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg 1995;22:8-14.
17. Lee JD, Kim DI, Lee JT, Chang JW, Park CY. Indium-111-pentetreotide imaging in intra-axial brain tumors: Comparison with thallium-201 SPECTand MRI. J Nucl Med 1995;36:537-41.
18. Hervas I, Perez-Velasco R, Bello P, Mateo A. In-111 octreotide scintigraphy in adult medulloblastoma. Clin Nucl Med 2003;28:343-4.
19. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394-403.
20. Mineura K, Sasajima T, Kowada M, Shishido F, Uemura K. Demonstration of cerebral radiation injury with metabolic positron emission tomography images. Pediatr Neurosurg - 92 1991;17:200-2.
21. Haldemann AR, Rosler H, Barth A, Waser B, Geiger L, Godoy N, et al. Somatostatin receptor scintigraphy in central nervous system tumors: Role of blood-brain barrier permeability. J Nucl Med 1995;36:403-10.
22. Rollins N, Mendelsohn D, Mulne A, Barton R, Diehl J, Reyes N, et al. Recurrent medulloblastoma: Frequency of tumor enhancement on Gd-DTPA MR imaging. Am J Roentgenol 1990;155:153-7.
23. Adams S, Baum RP. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med 2000;44:59-67.
24. Anderson NE. Late complications in childhood central nervous system tumour survivors. Curr Opin Neurol 2003;16:677-83.
25. Martelli H, Ricard M, Larroquet M, Wioland M, Paraf F, Fabre M, et al. Intraoperative localization of neuroblastoma in children with 123I- or 125I-radiolabeled metaiodobenzylguanidine. Surgery 1998;123:51-7.
26. Caglar K, Unal S, Cetinkaya A, Gumruk F, Yetgin S. Acute lymphoblastic leukemia as a second malignant neoplasm in a child with medulloblastoma. Pediatr Hematol Oncol 2003;20:535-7.
27. Strojan P, Popovic M, Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: Report of five cases and review of the literature. Int J Radiat Oncol Biol Phys 2000;48:65-73.
28. Rostomily RC, Halligan J, Geyer R, Stelzer K, Lindsley K, Berger MS. Permanent low-activity (125)I seed placement for the treatment of pediatric brain tumors: Preliminary experience. Pediatr Neurosurg 2001;34:198-205.
29. 131I-radiolabelled monoclonal antibodies. J Neuro-Oncol 1998;38:225-32.
30. Cokgor I, Akabani G, Kuan CT, Friedman AH, Coleman RE, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-72.
31. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
32. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33.
33. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486-93.
34. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabelled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 2003;9:1868-76.